Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. U.S. Food and Drug Administration. Emergency Use Authorization (EUA) for Nirmatrelvir-ritonavir (nirmatrelvir and ritonavir). FDA; 2023, https://www.fda.gov/media/155049/download.
2. Shah MM, Joyce B, Plumb ID, et al. Nirmatrelvir-ritonavir associated with decreased hospitalization rate among adults with COVID-19 — United States, April–September 2022. Am J Transplant. 2023;23(1):150-155. https://doi.org/10.1016/j.ajt.2022.12.004.
3. Lam CN, Nicholas W, Torre ADL, et al. Factors associated with parents’ willingness to vaccinate their children against COVID-19: the LA pandemic surveillance cohort study. AIMSPH. 2022;9(3):482-489. https://doi.org/10.3934/publichealth.2022033.
4. Centers for Disease Control and Prevention (CDC). Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.
5. Zargar AH, Kalra S, K M PK, et al. Rising cost of insulin: a deterrent to compliance in patients with diabetes mellitus. Diabetes Metab Syndr: Clin Res Rev. 2022;16(8):102528. https://doi.org/10.1016/j.dsx.2022.102528.